Full Text View
Tabular View
Study Results
Related Studies
Evaluate Safety and Efficacy of Paricalcitol in Reducing Serum Intact Parathyroid Hormone in Chronic Kidney Disease
This study has been completed.
Study NCT01071070   Information provided by Abbott

First Received on November 25, 2009.   Last Updated on December 20, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Kidney Disease
Additional conditions recognized in this trial
Kidney Diseases
Kidney Failure, Chronic
Renal Insufficiency, Chronic
More general conditions related to this trial
Renal Insufficiency
Urologic Diseases
Interventions listed in this trial
paricalcitol
Additional drug interventions recognized in this trial
Ergocalciferols
Hormones
More general drug interventions related to this trial
Bone Density Conservation Agents
Growth Substances
Hormones, Hormone Substitutes, and Hormone Antagonists
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Vitamins
Sponsors listed in this trial
Abbott


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services